The future of biologic agents in the treatment of Sjogren's syndrome

被引：27
|
作者：
Meijer, Jiska M.
Pijpe, Justin
Bootsma, Hendrika
Vissink, Arjan
Kallenberg, Cees G. M.
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Oral & Maxillofacial Surg, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands
来源：
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY | 2007年 / 32卷 / 03期
关键词：
Sjogren's syndrome; biological agent; treatment; monoclonal antibody; therapy; autoimmune disease;
D O I：
10.1007/s12016-007-8005-6
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjogren's syndrome (SS) and the current availability of various biological agents (anti-TNF-alpha, IFN-alpha, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.
引用
收藏
页码：292 / 297
页数：6
相关论文
共 50 条
  • [1] Biologic treatment in Sjogren's syndrome
    Sada, Pablo Ruiz
    Isenberg, David
    Ciurtin, Coziana
    RHEUMATOLOGY, 2015, 54 (02) : 219 - 230
  • [2] The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
    Jiska M. Meijer
    Justin Pijpe
    Hendrika Bootsma
    Arjan Vissink
    Cees G. M. Kallenberg
    Clinical Reviews in Allergy & Immunology, 2007, 32 : 292 - 297
  • [3] Present and future of biologic drugs in primary Sjogren's syndrome
    Sambataro, Domenico
    Sambataro, Gianluca
    Dal Bosco, Ylenia
    Polosa, Riccardo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (01) : 63 - 75
  • [4] Biologic therapy in Sjogren's syndrome
    Shao, Qin
    CLINICAL RHEUMATOLOGY, 2021, 40 (06) : 2143 - 2154
  • [5] Biologic Therapies in Primary Sjogren's Syndrome
    Bowman, S. J.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (10) : 1997 - 2008
  • [6] Treatment Guidelines for Rheumatologic Manifestations of Sjogren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain
    Carsons, Steven E.
    Vivino, Frederick B.
    Parke, Ann
    Carteron, Nancy
    Sankar, Vidya
    Brasington, Richard
    Brennan, Michael T.
    Ehlers, William
    Fox, Robert
    Scofield, Hal
    Hammitt, Katherine M.
    Birnbaum, Julius
    Kassan, Stuart
    Mandel, Steven
    ARTHRITIS CARE & RESEARCH, 2017, 69 (04) : 517 - 527
  • [7] Treatment of Sjogren's syndrome: current therapy and future directions
    Fox, Robert I.
    Fox, Carla M.
    Gottenberg, Jacques Eric
    Doerner, Thomas
    RHEUMATOLOGY, 2021, 60 (05) : 2066 - 2074
  • [8] Future treatments for Sjogren's syndrome
    Pers, Jacques-Olivier
    Saraux, Alain
    PRESSE MEDICALE, 2016, 45 (06): : E193 - E200
  • [9] Issues Related to Clinical Trials of Oral and Biologic Disease-Modifying Agents for Sjogren's Syndrome
    Carsons, Steven E.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2008, 34 (04) : 1011 - +
  • [10] Treatment of Sjogren's syndrome
    Saraux, A.
    REVUE DE MEDECINE INTERNE, 2010, 31 : S16 - S17
12345